Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS Caremark 4th-Quarter Profit Rose 2.6% Amid Continued Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 01:52pm CEST
   By Tess Stynes 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.

For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.

CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s (>> Walgreen Company) and pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that has since been resolved.

A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.

CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.

On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.

Shares closed Tuesday at $51.72 and were inactive premarket.

Write to Tess Stynes at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
06:23p CVS HEALTH : responds to nation's opioid crisis
03:36p CVS HEALTH : Sen. Manchin Issues Statement on CVS Decision to Make Proactive Cha..
01:08p CVS HEALTH : to limit painkiller prescriptions to a 7-day supply
03:33a CVS HEALTH : to limit amount and strength of opioid painkillers for first-time u..
09/22 CVS HEALTH : to limit opioid access to customers
09/22 CVS HEALTH : to limit opioid prescriptions to seven-day supplies
09/22 CVS HEALTH : becomes first retailer to limit opioid prescriptions to 7 days
09/22 CVS HEALTH : How national drugstore plans to help in fight against opioid abuse
09/22DJWHAT'S NEWS : Business & Finance -- WSJ
09/22 CVS HEALTH : drug stores announce they are restricting opioid prescriptions
More news
News from SeekingAlpha
09/21 CVS moves to restrict access to opioid painkillers
09/21 10 Dividend Growth Stocks For September 2017
09/20 Amazon eyes pharmacy benefit sector
09/19 CVS Health declares $0.50 dividend
09/19 I Was Right, There Was An Alpha Opportunity With My 15 Dividend Achievers
Financials ($)
Sales 2017 184 B
EBIT 2017 10 089 M
Net income 2017 5 289 M
Debt 2017 24 744 M
Yield 2017 2,48%
P/E ratio 2017 15,74
P/E ratio 2018 13,68
EV / Sales 2017 0,57x
EV / Sales 2018 0,55x
Capitalization 80 949 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 87,0 $
Spread / Average Target 9,2%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH0.82%80 949
WALGREENS BOOTS ALLIANCE-4.74%83 906
EXPRESS SCRIPTS HOLDING CO-10.13%35 976
MCKESSON CORPORATION8.63%32 382
CARDINAL HEALTH INC-7.31%21 012
AMERISOURCEBERGEN CORP.1.68%17 759